✨ Onyx Summary Geron Corporation announced a strategic restructuring plan that will reduce its workforce by approximately one-third and is expected to lower full-year 2026 operating expenses below 2025 levels, with savings beginning in the first quarter of 2026. The move reflects a shift toward tighter financial discipline while maintaining focus
✨ Onyx Summary Sinaptica Therapeutics received funding from the Centre for Aging + Brain Health Innovation (CABHI), in partnership with Baycrest, to support development and validation of its personalized, non-invasive neuromodulation system for Alzheimer’s disease. The funding deepens Sinaptica’s collaboration with Baycrest and supports advancement toward clinical readiness and future
A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
✨ Onyx Summary Ocugen said CEO and co-founder Dr. Shankar Musunuri will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, where he will discuss the company’s modifier gene therapy platform and its potential applications in inherited retinal and age-related blindness diseases. The presentation, alongside investor
✨ Onyx Summary Lexicon Pharmaceuticals announced the publication of preclinical data in the Journal of the Endocrine Society validating Acyl-CoA Synthetase 5 (ACSL5) as a therapeutic target for obesity and chronic weight management, supporting advancement of its investigational oral inhibitor LX9851. The findings, combined with Lexicon’s March 2025 worldwide licensing
Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).
✨ Onyx Summary Guardant Health launched FPG 360, an in-house liquid biopsy testing service at Policlinico Gemelli in Rome, enabling on-site use of Guardant360 CDx technology for routine care and clinical research within one of Italy’s largest oncology centers. The partnership extends Guardant’s European public-private model by embedding liquid
“We’re really on the precipice of moving the company into that next stage of maturity,” Dr. Mike Exton
✨ Onyx Summary Geron presented new ASH 2025 data reinforcing RYTELO (imetelstat) activity in lower-risk MDS and myelofibrosis, including analyses linking early treatment-emergent cytopenias to subsequent hemoglobin gains and transfusion independence in the IMerge program. Updated long-term outcomes from IMerge and biomarker findings from IMbark further support ongoing development of imetelstat
✨ Onyx Summary Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial showing that REC-4881, an investigational allosteric MEK1/2 inhibitor, delivered rapid and durable reductions in polyp burden in patients with familial adenomatous polyposis, with effects persisting after treatment cessation. The results represent the first clinical validation
✨ Onyx Summary Legend Biotech Corporation reported updated ASH 2025 data showing CARVYKTI® achieved a median progression-free survival of 50.4 months in triple-class-exposed multiple myeloma patients with three prior lines of therapy, with translational analyses indicating stronger immune fitness when used earlier in treatment. The company also presented first-in-human Phase
✨ Onyx Summary Lexicon Pharmaceuticals announced that new clinical data from the SOTA-P-CARDIA trial evaluating the effect of sotagliflozin on adipose tissue distribution in non-diabetic patients with HFpEF will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum in December 2025. The presentation adds to prior cardiovascular data on
✨ Onyx Summary Guardant Health will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium (Dec. 9–12, 2025) highlighting data across Guardant Reveal and Guardant360 Liquid that evaluate tissue-free, blood-based testing for minimal residual disease detection, treatment response assessment, relapse risk prediction, and breast cancer subtyping from early-stage
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
✨ Onyx Summary Perspective Therapeutics announced that updated safety and preliminary efficacy data from its [212Pb]VMT-α-NET program in advanced SSTR2-expressing neuroendocrine tumors have been accepted for presentation at the ASCO Gastrointestinal Cancers Symposium 2026. The accepted abstract builds on previously reported interim results showing a favorable safety profile and early
